{"id":"W3166474048","doi":"10.1200/jco.2021.39.15_suppl.2015","title":"Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Bevacizumab; Nivolumab; Internal medicine; Oncology; Progression-free survival; Overall survival; Gastroenterology; Surgery; Chemotherapy; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00147425,0.001451703,0.002111574,0.0004034329,0.0003252547,0.001002713,0.0007720029,0.001282558,0.005483251],"category_scores_gemma":[0.001235053,0.0007706438,0.001034215,0.0003321394,0.0008731493,0.0008072651,0.0004598349,0.002441549,0.001249075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001299238,"about_ca_system_score_gemma":0.001474816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001369558,"about_ca_topic_score_gemma":0.003977044,"domain_scores_codex":[0.9995746,0.0001851081,0.00002024347,0.00009291113,0.0000376922,0.00008946909],"domain_scores_gemma":[0.9993473,0.00009276146,0.0001442972,0.00005698508,0.00004793968,0.0003107954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9471405,0.02233508,0.001310082,0.0002928064,0.0005660622,0.00004502695,0.00006519708,0.0004907646,0.005872023,0.0001190713,0.001532889,0.02023059],"study_design_scores_gemma":[0.8331943,0.1612614,0.002792681,0.0000198404,0.0002551386,0.00005358839,0.0000228241,0.0004335859,0.000644047,0.0002075293,0.001099634,0.00001543836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877586,0.001611821,0.0005485969,0.0005731274,0.0004837183,0.00583933,0.001589469,0.0001264835,0.001468794],"genre_scores_gemma":[0.9823417,0.001219478,0.001929573,0.001329415,0.0002562059,0.006991675,0.001870116,0.00003877017,0.004023045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005483251,"threshold_uncertainty_score":0.01834327,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1183273163117005,"score_gpt":0.4949731528395728,"score_spread":0.3766458365278722,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}